ScholarIQanswers from OpenAlex & ORCID
Fedor Moiseenko
ResearcherPublications, citations & collaboration network
Fedor Moiseenko is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Fedor Moiseenko have?
ScholarIQindexed works
Fedor Moiseenko has 216 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Fedor Moiseenko have?
ScholarIQcitation count
Fedor Moiseenko has 33,670 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Fedor Moiseenko?
ScholarIQh-index
Fedor Moiseenko has an h-index of 36 in OpenAlex.
What is the i10-index of Fedor Moiseenko?
ScholarIQi10-index
Fedor Moiseenko has an i10-index of 52 in OpenAlex.
What is the ORCID of Fedor Moiseenko?
ScholarIQorcid
The ORCID for Fedor Moiseenko is on the source record.
What is the OpenAlex record for Fedor Moiseenko?
ScholarIQopenalex
The OpenAlex for Fedor Moiseenko is on the source record.
What are the most-cited papers on Fedor Moiseenko?
ScholarIQmost cited works
Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer
Ying Cheng, Liang Han, Lin Wu, Jun Chen, Hongmei Sun, Guilan Wen, Yinghua Ji, Mikhail Dvorkin, Jianhua Shi, Zhijie Pan, Jinsheng Shi, Xicheng Wang, Yuansong Bai, Tamar Melkadze, Yueyin Pan, Xuhong Min, Maksym Viguro, Xingya Li, Yanqiu Zhao, Junquan Yang, Tamta Makharadze, Ekaterine Arkania, Wenying Kang, Qingyu Wang, Jun Zhu, ASTRUM-005 Study Group, Xiubao Ren, Vladimer Kuchava, Guoping Sun, Gaofeng Li, Lin Wen, Tao Zhang, Hakan Harputluoğlu, İrfan Çiçin, Guosheng Feng, Yanrong Hao, Kejing Ying, Ping Sun, Aihong Zhong, Guangyu An, Yan Wang, Chun Chen, Sheng Yang, Zhendong Chen, Konstantin Penkov, Yuriy Semegen, Oleg Kobziev, Feng Luo, Peiguo Cao, Zhixiong Yang, Min Fan, Wen Li, Robert Mróz, А. Л. Акопов, Tuncay Göksel, Mahmut Gümüş, Wenlei Zhuo, Jian Fang, Hui Zhao, Lin Zhong, Yanping Hu, Yarong Li, Shuqun Zhang, Jiuwei Cui, Н. В. Коваленко, Çağatay Arslan, Devrim Cabuk, Alev Türker, Igor Bondarenko, Yevhen Hotko, O. Goloborodko, Dongji Chen, Mengzhao Wang, Zhuang Yu, Jun‐Guo Lu, Liyan Jiang, Hao Xiong, Davit Giorgadze, Sergey Orlov, Ahmet Bılıcı, Ivan Sinelnikov, Gongyan Chen, Yue Lu, Xiaoli Zhu, Liqin Lu, Mariam Zhvania, Małgorzata Ułańska, Igor Lifirenko, Timur Andabekov, Maria Smagina, Fedor Moiseenko, Yüksel Ürün, Ligong Nie, Bangwei Cao, Zhenyu You, Haixin Huang, Shenpeng Ying, Alexandre Tavartkiladze, Tariel Kitiashvili, Amiran Matitashvili
Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein–Overexpressing Advanced Nonsquamous <i>EGFR</i> -Wildtype Non–Small Cell Lung Cancer in the Phase II LUMINOSITY Trial
D. Ross Camidge, Jair Bar, Hidehito Horinouchi, Jonathan W. Goldman, Fedor Moiseenko, Е. А. Филиппова, İrfan Çiçin, Tudor–Eliade Ciuleanu, Nathalie Daaboul, Chunling Liu, Penelope A. Bradbury, Mor Moskovitz, Nuran Katgı, Pascale Tomasini, Alona Zer, Nicolas Girard, Kristof Cuppens, Ji‐Youn Han, Shang‐Yin Wu, Shobhit Baijal, Aaron S. Mansfield, Chih‐Hsi S. Kuo, Kazumi Nishino, Se‐Hoon Lee, David Planchard, Christina S. Baik, Martha Li, Peter Ansell, Summer Xia, Ellen Bolotin, Jim Looman, Christine K. Ratajczak, Shun Lü
Investigation of the mechanisms of resistance to osimertinib in patients with T790M-associated NSCLC
M. Stepanova, Fedor Moiseenko, A.S. Zhabina, В. В. Клименко, N. Rysev, A.V. Myslik, E.V. Artemieva, Ksenya V. Shelekhova, An.A. Bogdanov, Nikita Volkov, В. Моисеенко